转移性非小细胞肺癌的一线管理：印度视角
First-line management of metastatic non-small cell lung cancer: An Indian perspective.
作者信息
Ghadyalpatil Nikhil Suresh, Pandey Avinash, Krishnamani Iyer, Srinivas Chilukuri, Rafiq Shabnam J, Hingmire Sachin S, Maturu Nagarjuna, Reddy Ragotham, Kumar Kiran K, Sreekanth K, Gurram Bharath Chandra, Parikh P M
机构信息
Department of Medical Oncology, Yashoda Hospital, Hyderabad, Telangana, India.
Department of Medical Oncology, IGIMS, Patna, Bihar, India.
出版信息
South Asian J Cancer. 2019 Apr-Jun;8(2):73-79. doi: 10.4103/sajc.sajc_294_18.
Abstract
Lung cancer has been the most common cancer in the world for several decades. The non-small cell lung cancer (NSCLC) constitutes approximately about 80% of the total cases of lung cancer. Therapeutic interventions in NSCLC have shifted to the target-based approach from histology-based approach, and this has completely changed the face of the management of NSCLC. Developing countries, such as India, have very limited data compiled about the prevalence and treatment practices of lung cancer, despite a large burden of the disease. However, in recent times, there has been a lot of data generated in this regard. This article is an attempt to collate and shine light on the available data for the first-line treatment of NSCLC in India keeping in mind the current standards of care in this area.
摘要
几十年来，肺癌一直是全球最常见的癌症。非小细胞肺癌（NSCLC）约占肺癌总病例的80%。NSCLC的治疗干预已从基于组织学的方法转向基于靶点的方法，这彻底改变了NSCLC的治疗面貌。尽管印度等发展中国家肺癌负担沉重，但关于肺癌患病率和治疗方法的汇编数据非常有限。然而，最近在这方面已经产生了大量数据。本文旨在整理并揭示印度NSCLC一线治疗的现有数据，同时牢记该领域当前的护理标准。
相似文献
1
First-line management of metastatic non-small cell lung cancer: An Indian perspective.转移性非小细胞肺癌的一线管理：印度视角
South Asian J Cancer. 2019 Apr-Jun;8(2):73-79. doi: 10.4103/sajc.sajc_294_18.
2
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).中国不可切除的IIIB/IV期非鳞状非小细胞肺癌患者一线治疗模式及基因畸变检测状况的多中心调查（CTONG 1506）
BMC Cancer. 2017 Jul 3;17(1):462. doi: 10.1186/s12885-017-3451-x.
3
First-line therapy outcomes in patients with advanced stage nonsmall cell lung cancer treated at nongovernment tertiary care centrer in India: Experience from a real world practice.印度非政府三级医疗中心治疗的晚期非小细胞肺癌患者的一线治疗结果：来自真实世界实践的经验。
Indian J Cancer. 2017 Jan-Mar;54(1):182-186. doi: 10.4103/0019-509X.219594.
4
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.表皮生长因子受体-酪氨酸激酶抑制剂在非小细胞肺癌中的更新。
J Chin Med Assoc. 2013 May;76(5):249-57. doi: 10.1016/j.jcma.2013.01.010. Epub 2013 Mar 22.
5
Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.晚期非小细胞肺癌患者的医疗资源使用情况：PIvOTAL回顾性观察研究
BMC Health Serv Res. 2018 Mar 1;18(1):147. doi: 10.1186/s12913-018-2946-8.
6
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
7
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.非小细胞肺癌的靶向治疗：聚焦于ALK/ROS1酪氨酸激酶抑制剂
Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6.
8
Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.瑞士晚期非小细胞肺癌患者的表皮生长因子受体和间变性淋巴瘤激酶检测及突变发生率：对实际临床实践的综合评估
Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12721. Epub 2017 May 30.
9
Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice.美国社区肿瘤临床实践中含铂治疗后晚期非小细胞肺癌的治疗模式
Clin Lung Cancer. 2016 Sep;17(5):449-460.e7. doi: 10.1016/j.cllc.2016.03.008. Epub 2016 Mar 29.
10
Medical management of lung cancer: Experience in China.肺癌的医学管理：中国的经验。
Thorac Cancer. 2015 Jan;6(1):10-6. doi: 10.1111/1759-7714.12168. Epub 2015 Jan 7.
引用本文的文献
1
Association Between Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study.既往接受过治疗的晚期非小细胞肺癌患者中阿帕替尼单药治疗的基因变异与疗效之间的关联：一项真实世界回顾性研究
Int J Gen Med. 2021 Jun 21;14:2703-2714. doi: 10.2147/IJGM.S303717. eCollection 2021.
2
WZ4003 sensitizes non-small cell lung cancer cells to gefitinib via inhibition of ARK5 and epithelial-to-mesenchymal transition.WZ4003通过抑制ARK5和上皮-间质转化使非小细胞肺癌细胞对吉非替尼敏感。
Am J Transl Res. 2020 Nov 15;12(11):7377-7385. eCollection 2020.
3
Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor.安罗替尼用于标准治疗方案后进展的晚期非小细胞肺癌患者的疗效和安全性及疗效预测指标的初步分析
Cancer Manag Res. 2020 Jul 12;12:5641-5650. doi: 10.2147/CMAR.S253366. eCollection 2020.
本文引用的文献
1
Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung.克唑替尼在印度肺腺癌患者中针对免疫组化证实的棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶融合基因的临床疗效研究。
South Asian J Cancer. 2018 Jan-Mar;7(1):61-64. doi: 10.4103/sajc.sajc_215_17.
2
ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience.ROS1重排的非小细胞肺癌与克唑替尼：一项印度的经验。
Indian J Cancer. 2017 Apr-Jun;54(2):436-438. doi: 10.4103/ijc.IJC_269_17.
3
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?吉非替尼在表皮生长因子受体激活突变阳性非小细胞肺癌中的疗效：外显子19缺失与外显子21突变有何不同？
Lung India. 2018 Jan-Feb;35(1):27-30. doi: 10.4103/lungindia.lungindia_201_17.
4
Anaplastic lymphoma kinase status in lung cancers: An immunohistochemistry and fluorescence hybridization study from a tertiary cancer center in India.肺癌中间变性淋巴瘤激酶状态：来自印度一家三级癌症中心的免疫组织化学和荧光杂交研究。
Indian J Cancer. 2017 Jan-Mar;54(1):231-235. doi: 10.4103/0019-509X.219533.
5
New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.间变性淋巴瘤激酶阳性非小细胞肺癌的新见解
Indian J Cancer. 2017 Jan-Mar;54(1):203-208. doi: 10.4103/ijc.IJC_72_17.
6
Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience.IV期肺腺癌患者的临床特征与转归：一家三级癌症中心的经验
Indian J Cancer. 2017 Jan-Mar;54(1):197-202. doi: 10.4103/0019-509X.219595.
7
Clinical profile of nonsmall cell lung carcinoma patients treated in a single unit at a tertiary cancer care center.
Indian J Cancer. 2017 Jan-Mar;54(1):193-196. doi: 10.4103/0019-509X.219591.
8
First-line therapy outcomes in patients with advanced stage nonsmall cell lung cancer treated at nongovernment tertiary care centrer in India: Experience from a real world practice.印度非政府三级医疗中心治疗的晚期非小细胞肺癌患者的一线治疗结果：来自真实世界实践的经验。
Indian J Cancer. 2017 Jan-Mar;54(1):182-186. doi: 10.4103/0019-509X.219594.
9
Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent.
Indian J Cancer. 2017 Jan-Mar;54(1):144-147. doi: 10.4103/ijc.IJC_186_17.
10
Epidermal growth factor receptor positive lung cancer: The nontrial scenario.
Indian J Cancer. 2017 Jan-Mar;54(1):132-135. doi: 10.4103/0019-509X.219583.
Zotero 插件